Lana Pine

Despite the limitations of the study, non-adherence rates were significantly reduced in patients observed throughout the 3 years, indicating that the methods developed and deployed were successful.

Voclosporin (LUPKYNIS), in combination with an existing immunosuppressive therapy regimen, works to safely and effectively treat adult patients with lupus nephritis.

Investigators aimed to improve the quality of care by creating effective management plans using the goals of both the patient and physician. During the course of the Elderly Multimorbidity Clinic (EMC) program, 75% of patients accomplished at least 1 of their goals. Unfortunately, no sustained benefits were observed because of low follow-up.

Investigators found "improved outcomes for patients with rheumatic and musculoskeletal diseases after COVID-19 diagnosis in more recent months of the pandemic compared with earlier months, including lower risks of death, respiratory failure, and renal failure."

Previously proven to be an effective and well-tolerated treatment for patients with RA, baricitinib can also help patients reduce joint damage progression and erosion.

Coupled with the fact that there were no new safety concerns identified, these findings further solidify the safety and effectiveness of abatacept for RA patients.

In this phase 3, 104-week, randomized, double-blind, placebo-controlled, post-approval commitment study, Efficacy and Safety of Belimumab in Adult Patients with Active Lupus Nephritis (BLISS-LN) evaluated the efficacy and safety of intravenous BENLYSTA in conjunction with standard therapy and found that it was more effective than a placebo.